semaglutide after breast cancer The Impact and Safety of GLP‐1 Agents and Popular weight loss drugs could

This berry, o

and (2) a parallel-group intervention open-label trial of once-weekly 1.0 mg subcutaneous injection of semaglutide (Ozempic

Poor sleep increases ghrelin (hunger hormone) and decreases leptin (satiety hormone), directly undermining dietary adherence

The agents pharmacologic versatility is reflected in its multiple formulations, including oral immediate-release (IR), extended-release (ER), transdermal, and topical gel preparations, each offering distinct pharmacokinetic and tolerability advantages

Japanese J Pharmacol

The findings suggest the risks of those conditions are higher in patients specifically taking GLP-1s rather than other weight loss medications that work differently